Neuroscience
A report from Fierce BioTech:
Third Rock Ventures Launches SAGE Therapeutics to Address CNS Disorders with Critical Unmet Needs
Posted October 18, 2011
[snippet]
"Third Rock Ventures, LLC today announced the formation of SAGE Therapeutics. The company was launched with a $35 million Series A financing. SAGE's efforts focus on advancing a broad pipeline of new, critically needed treatments for some of the most disabling central nervous system (CNS) disorders such as schizophrenia, depression, pain and traumatic brain injury (TBI). SAGE Therapeutics is founded on a proprietary Positive and Negative Allosteric Modulator (PANAM) chemistry platform that will enable the rapid development of a novel class of allosteric receptor modulators. Steven Paul, M.D., the former executive vice president for science and technology and president of Lilly Research Laboratories and a former scientific director of the National Institute of Mental Health (NIMH) and Douglas Covey, Ph.D., professor of biochemistry at the Washington University School of Medicine, are founders of the company."
[snippet]
Read the full report
- Free Full-text Access To Sage Neuroscience Journals
Following their free access promotion to their psychology journals (ongoing to the end of this month), the academic publisher Sage is now offering free full-text access to its range of neuroscience and neurology journals, including: the American Journal...
- Epilepsy News
A press release from the NIH: Ultrathin flexible brain implant offers unique look at seizures in NIH-funded research 13 November 2011 [snippet] Researchers funded by the National Institutes of Health have developed a flexible brain implant that could...
- Tc-5214 Depression Phase Iii Results
From Fierce Biotech: Key AZ/Targacept depression drug flunks first Phase III test By John Carroll November 8, 2011 — 6:49am ET [snippet] "The high-profile depression drug TC-5214 has failed the first in a string of Phase III studies, dealing AstraZeneca's...
- Neuropsychology Abstract Of The Day: Aging And Mci Screening
Today's recommended read deals with an important neuropsychological assessment issue in the domain of aging and the potential to identify the presence of cognitive problems that might (emphasis on "might" - such findings in a screen are not definitive)...
- Business World: "the Brain Industry"
From The Seattle Times:Biotech Watch: Biotech companies scramble to develop brain-related products By Steve Johnson Knight Ridder Newspapers The Seattle Times Monday, July 25, 2005 SAN JOSE, Calif. — The prospect of a billion people nearing the age...
Neuroscience
SAGE Therapeutics
A report from Fierce BioTech:
Third Rock Ventures Launches SAGE Therapeutics to Address CNS Disorders with Critical Unmet Needs
Posted October 18, 2011
[snippet]
"Third Rock Ventures, LLC today announced the formation of SAGE Therapeutics. The company was launched with a $35 million Series A financing. SAGE's efforts focus on advancing a broad pipeline of new, critically needed treatments for some of the most disabling central nervous system (CNS) disorders such as schizophrenia, depression, pain and traumatic brain injury (TBI). SAGE Therapeutics is founded on a proprietary Positive and Negative Allosteric Modulator (PANAM) chemistry platform that will enable the rapid development of a novel class of allosteric receptor modulators. Steven Paul, M.D., the former executive vice president for science and technology and president of Lilly Research Laboratories and a former scientific director of the National Institute of Mental Health (NIMH) and Douglas Covey, Ph.D., professor of biochemistry at the Washington University School of Medicine, are founders of the company."
[snippet]
Read the full report
- Free Full-text Access To Sage Neuroscience Journals
Following their free access promotion to their psychology journals (ongoing to the end of this month), the academic publisher Sage is now offering free full-text access to its range of neuroscience and neurology journals, including: the American Journal...
- Epilepsy News
A press release from the NIH: Ultrathin flexible brain implant offers unique look at seizures in NIH-funded research 13 November 2011 [snippet] Researchers funded by the National Institutes of Health have developed a flexible brain implant that could...
- Tc-5214 Depression Phase Iii Results
From Fierce Biotech: Key AZ/Targacept depression drug flunks first Phase III test By John Carroll November 8, 2011 — 6:49am ET [snippet] "The high-profile depression drug TC-5214 has failed the first in a string of Phase III studies, dealing AstraZeneca's...
- Neuropsychology Abstract Of The Day: Aging And Mci Screening
Today's recommended read deals with an important neuropsychological assessment issue in the domain of aging and the potential to identify the presence of cognitive problems that might (emphasis on "might" - such findings in a screen are not definitive)...
- Business World: "the Brain Industry"
From The Seattle Times:Biotech Watch: Biotech companies scramble to develop brain-related products By Steve Johnson Knight Ridder Newspapers The Seattle Times Monday, July 25, 2005 SAN JOSE, Calif. — The prospect of a billion people nearing the age...